Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25540908 | 0.77 | MEN1 (0.39) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL19118274 | 0.77 | MEN1 (0.42) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL24859248 | 0.76 | — | — | |
| SCHEMBL22621463 | 0.76 | TSHR (0.39) | — | |
| SCHEMBL10245062 | 0.76 | TSHR (0.44) | — | |
| SCHEMBL20643785 | 0.76 | TSHR (0.39) | — | |
| SCHEMBL10245064 | 0.76 | TSHR (0.44) | — | |
| SCHEMBL11020293 | 0.75 | TSHR (0.38) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL2600181 | 0.74 | HRH4 (0.34) | — | |
| SCHEMBL1426138 | 0.73 | TSHR (0.46) | MEN1CYP3A4ALOX15KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-02-03 | — | — | US | disclosed |
| US-11174481-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20190256849-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | MEN1 4413/4885CYP3A4 4688/4885ALOX15 3678/4885 |
| US-20190256849-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | MEN1 4413/4885CYP3A4 4688/4885ALOX15 3678/4885 |
| US-11174481-B2 | Targeting ligands | FABP1, SNRPE, HAVCR2 | MEN1 4413/4885CYP3A4 4688/4885ALOX15 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.